%0 Journal Article
%T Short-Term Effects of Liraglutide versus Vildagliptin on Insulin Secretion and Sensitivity in Type 2 Diabetes: A Single Blinded Randomized Controlled Trial (LIRAVIS Study)
%A Martine Claude Etoa Etoga
%A Estelle Amandine Well
%A Simeon Pierre Choukem
%A Mesmin Dehayem
%A Francine Mendane Mekobe
%A Anne Boli Ongmeb
%A Astasselbe Hadja Inna
%A Jean Claude Mbanya
%A Eugene Sobngwi
%J Journal of Diabetes Mellitus
%P 45-57
%@ 2160-5858
%D 2023
%I Scientific Research Publishing
%R 10.4236/jdm.2023.131005
%X <strong>Background:</strong> We aimed to evaluate the short-term metabolic effects of a GLP-1a, (liraglutide) versus a DPP-4i, (vildagliptin) in a group of sub-Saharan type 2 diabetes patients. <strong>Methods:</strong> We conducted a randomized controlled single blinded clinical trial in 14 uncontrolled type 2 diabetes patients (HbA1c ¡Ý 53 mmol/mol) with mean duration of diabetes of 8 [1 - 12] years and median age of 57 [49 - 61] years. Baseline treatment consisted of metformin in monotherapy or metformin plus sulfonylureas. Participants were randomly allocated to 2 groups of add-on 1.2 mg/day subcutaneous liraglutide in group 1 or 100 mg/day of oral vildagliptin in group 2 for 2 weeks. In all participants, insulin secretion in response to mixed meal tolerance test, insulin sensitivity by 80 mU/m<sup>2</sup>/min hyperinsulinemic-euglycemic clamp, body composition, and lipid profile were measured before and after intervention. <strong>Results:</strong> At the end of intervention, insulin sensitivity remained unchanged both with liraglutide from 6.6 [4.2 - 7.9] to 6.9 [4.3 - 10.8] mg/kg/min; p = 0.61 and vildagliptin from 7.1 [5.3 - 9.0] to 6.5 [5.6 - 9.4] mg/kg/min (p = 0.86). The area under the C-peptide curve varied from 5.5 [1.0 - 10.9] to 14.9 [10.8 - 17.2] nmol/L/120min, p = 0.09 in group 1 and from 1.1 [0.5 - 14.1] to 13.0 [9.6 - 16.9] nmol/L/120min (p = 0.17) in group 2. LDL Cholesterol levels decreased significantly with liraglutide from 0.85 g/L [0.51 - 1.02] to 0.54 g/L [0.50 - 0.73] (p = 0.04) but not with Vildagliptin. Body weight tended to decrease in group 1 (<span lang=\"EN-US\">&amp;#8722;</span>0.6 kg) versus modest increase in group 2 (+1.1 kg). <strong>Conclusion:</strong> Short-term metabolic effects of Liraglutide and Vildagliptin add-on therapy are comparable in sub-Saharan type 2 diabetes patients with a more favorable trend for Liraglutide on body weight, lipid profile, and insulin secretion.
%K Insulin Sensitivity
%K Insulin Secretion
%K Liraglutide
%K Vildagliptin
%K Incretinomimetics
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=122947